USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SIRNAOMICS, INC.
Address:
401 PROFESSIONAL DR, STE 130
GAITHERSBURG, MD 20879-3445
Phone:
N/A
URL:
N/A
EIN:
120883654
DUNS:
795480198
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,203,038.00 5

Award List:

Multi-targeted RNAi Therapeutic for Treatment of Breast Cancer

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$228,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Millions of women have been treated for or are living with breast cancer, and tens of thousands of women are expected to die from the disease each year. As breast cancer disease remains the second leading cause of cance r death in women (after lung cancer),… More

MULTI-TARGETED RNAI THERAPEUTICS FOR TREATMENT OF LUNG CANCER (NSCLC)

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$250,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer-related death in the United States and is responsible for over 160,000 patient deaths from their lung cancer this year, more than that of breast, colorectal, prostate, colon an d other cancers combined. With the existing… More

MULTI-TARGETED RNAI THERAPEUTICS FOR GLIOBLASTOMA MULTIFORME (GBM)

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$269,298.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Glioblastoma Multiforme (GBM), the most common brain cancer of adults, is among the most aggressive and deadly of neoplasm (WHO grade IV), and is accounted for more than 21% of all primary brain and CNS tumors. The annu al incidence of GBM in the United States is… More

Influenza Therapeutics Using siRNA Nanoparticle Technology

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$234,390.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Each year 10-20% of the US population is infected by the influenza virus, resulting in up to 40,000 deaths and 200,000 hospitalizations. While small molecules and vaccines have shown some benefit, the ability of the vir us to mutate rapidly allows escape from… More

Ligand Directed Transdermal siRNA Delivery to Improve Wound Healing

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$221,350.00
Agency:
HHS
Principal Investigator:
David M. Evans – 301-580-6193
Abstract:
DESCRIPTION (provided by applicant): The primary function of the skin is to serve as a protective barrier against the environment. Loss of the integrity of large portions of the skin as a result of wounds and wound-related infection may lead to major disability or even death. Every year in the… More